AstraZeneca signs an AI drug discovery deal worth up to $1.5 billion
insitro 2 days ago 29
AstraZeneca and insitro signed a worldwide exclusive research collaboration to discover novel drug targets and therapeutics for MASH and cardiomyopathies using insitro’s Virtual Human causal AI platform. insitro will get $40 million upfront and up to approximately $1.46 billion in milestone payments, plus single-digit royalties tied to global sales. AstraZeneca will handle clinical development, regulatory work, and commercialization while insitro advances AstraZeneca-nominated targets from discovery through development candidates.